April 25th 2024
“ARO-HIF2’s ability to target cancer cells, disrupting a key tumor-driving mechanism, illustrates the potential of siRNA technology in oncology,” says James Brugarolas, MD, PhD.
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Novel TKI/immunotherapy combo shows promise in advanced kidney cancer
April 22nd 2022Combination therapy with the novel TKI sitravatinib and the anti–PD-1 immune checkpoint inhibitor nivolumab showed promising efficacy and safety in patients with clear cell renal cell carcinoma and progression after antiangiogenic therapy.
Expert explains latest developments in surgical management of kidney cancer
March 18th 2022Gennady Bratslavsky, MD highlighted studies examining (neo)adjuvant immunotherapy in the setting of nephrectomy for locally advanced disease, such as the PROSPER (NCT03055013) and KEYNOTE-564 (NCT03142334) trials.
Dr. Steven Campbell on choosing between partial nephrectomy and radical nephrectomy
January 13th 2022On this episode of Cleveland Clinic’s Cancer Advances podcast, urologic surgeon Steven Campbell, MD, PhD, discusses the longstanding controversy between partial nephrectomy and radical nephrectomy for patients with localized kidney cancer.
Enrollment completed for phase 3 trial of cabozantinib plus atezolizumab in renal cell carcinoma
January 5th 2022The phase 3 CONTACT-03 trial is specifically accruing patients with inoperable, locally advanced or metastatic renal cell carcinoma with disease progression after receiving an immune checkpoint inhibitor as the immediate prior therapy.
Nivolumab plus ipilimumab linked to treatment-free survival boost in kidney cancer
January 3rd 2022A retrospective analysis of the phase 3 CheckMate-214 trial showed a treatment-free survival advantage with the immunotherapy combination versus the targeted therapy sunitinib in patients with advanced renal cell carcinoma.
Batiraxcept plus cabozantinib shows promise in kidney cancer
November 22nd 2021“The initial phase 1b data of batiraxcept in combination with cabozantinib are impressive and point toward the role of dual AXL and VEGF inhibition in the treatment of clear cell renal cell carcinoma,” said Eric Jonasch, MD.